Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SOK583A1 (Aflibercept Biosimilar) PFS in nAMD
NCT05161806Phase 3Completed
- Sponsor
- Sandoz
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Sandoz. Started Mar 2022; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05161806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161806.